EP3442529 - COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF LUNG CANCER [Right-click to bookmark this link] | |||
Former [2019/08] | COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | ||
[2020/22] | Status | No opposition filed within time limit Status updated on 02.04.2022 Database last updated on 02.09.2024 | |
Former | The patent has been granted Status updated on 23.04.2021 | ||
Former | Grant of patent is intended Status updated on 27.10.2020 | ||
Former | Examination is in progress Status updated on 08.10.2020 | ||
Former | Grant of patent is intended Status updated on 27.05.2020 | ||
Former | Examination is in progress Status updated on 23.08.2019 | ||
Former | Request for examination was made Status updated on 18.01.2019 | ||
Former | The international publication has been made Status updated on 20.10.2017 | ||
Former | unknown Status updated on 26.04.2017 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2019/08] | Inventor(s) | 01 /
BECKMANN, Richard Paul c/o Eli Lilly and Company P.O. Box 6288 Indianapolis Indiana 46206-6288 / US | 02 /
PATEL, Bharvin Kumar c/o Eli Lilly and Company P.O. Box 6288 Indianapolis Indiana 46206-6288 / US | [2019/08] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2019/08] | Application number, filing date | 17717990.0 | 05.04.2017 | [2019/08] | WO2017US26134 | Priority number, date | US201662321311P | 12.04.2016 Original published format: US 201662321311 P | [2019/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017180389 | Date: | 19.10.2017 | Language: | EN | [2017/42] | Type: | A1 Application with search report | No.: | EP3442529 | Date: | 20.02.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.10.2017 takes the place of the publication of the European patent application. | [2019/08] | Type: | B1 Patent specification | No.: | EP3442529 | Date: | 26.05.2021 | Language: | EN | [2021/21] | Search report(s) | International search report - published on: | EP | 19.10.2017 | Classification | IPC: | A61K31/444, A61K31/506, A61K31/55, A61P35/00, A61P35/02 | [2019/08] | CPC: |
A61K31/55 (EP,US);
A61K31/444 (EP,RU);
A61K31/4745 (US);
A61K31/506 (EP,US);
A61P35/00 (EP,RU,US);
A61P35/02 (EP);
| C-Set: |
A61K31/444, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP);
A61K31/55, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/08] | Extension states | BA | 12.11.2018 | ME | 12.11.2018 | Validation states | MA | 12.11.2018 | MD | 12.11.2018 | Title | German: | KOMBINATIONSTHERAPIE MIT NOTCH- UND CDK4/6-INHIBITOREN ZUR BEHANDLUNG VON LUNGENKREBS | [2020/22] | English: | COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF LUNG CANCER | [2020/22] | French: | TRAITEMENT D'ASSOCIATION À BASE D'INHIBITEURS DE NOTCH ET DE CDK4/6 POUR LE TRAITEMENT DU CANCER DU POUMON | [2020/22] |
Former [2019/08] | KOMBINATIONSTHERAPIE MIT NOTCH- UND CDK4/6-INHIBITOREN ZUR BEHANDLUNG VON KREBS | ||
Former [2019/08] | COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | ||
Former [2019/08] | TRAITEMENT D'ASSOCIATION À BASE D'INHIBITEURS DE NOTCH ET DE CDK4/6 POUR LE TRAITEMENT DU CANCER | Entry into regional phase | 12.11.2018 | National basic fee paid | 12.11.2018 | Designation fee(s) paid | 12.11.2018 | Examination fee paid | Examination procedure | 12.11.2018 | Examination requested [2019/08] | 12.11.2018 | Date on which the examining division has become responsible | 13.06.2019 | Amendment by applicant (claims and/or description) | 27.08.2019 | Despatch of a communication from the examining division (Time limit: M06) | 06.03.2020 | Reply to a communication from the examining division | 28.05.2020 | Communication of intention to grant the patent | 06.10.2020 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 28.10.2020 | Communication of intention to grant the patent | 08.03.2021 | Fee for grant paid | 08.03.2021 | Fee for publishing/printing paid | 08.03.2021 | Receipt of the translation of the claim(s) | Opposition(s) | 01.03.2022 | No opposition filed within time limit [2022/18] | Fees paid | Renewal fee | 12.11.2018 | Renewal fee patent year 03 | 21.04.2020 | Renewal fee patent year 04 | 15.04.2021 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 05.04.2017 | AL | 26.05.2021 | AT | 26.05.2021 | CY | 26.05.2021 | CZ | 26.05.2021 | DK | 26.05.2021 | EE | 26.05.2021 | FI | 26.05.2021 | HR | 26.05.2021 | LT | 26.05.2021 | LV | 26.05.2021 | MC | 26.05.2021 | MK | 26.05.2021 | NL | 26.05.2021 | PL | 26.05.2021 | RO | 26.05.2021 | RS | 26.05.2021 | SE | 26.05.2021 | SI | 26.05.2021 | SK | 26.05.2021 | SM | 26.05.2021 | TR | 26.05.2021 | BG | 26.08.2021 | NO | 26.08.2021 | GR | 27.08.2021 | IS | 26.09.2021 | PT | 27.09.2021 | [2024/29] |
Former [2024/22] | HU | 05.04.2017 | |
AL | 26.05.2021 | ||
AT | 26.05.2021 | ||
CY | 26.05.2021 | ||
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
MC | 26.05.2021 | ||
MK | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SI | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2024/20] | HU | 05.04.2017 | |
AL | 26.05.2021 | ||
AT | 26.05.2021 | ||
CY | 26.05.2021 | ||
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
MC | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SI | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2024/18] | HU | 05.04.2017 | |
AL | 26.05.2021 | ||
AT | 26.05.2021 | ||
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
MC | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SI | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2023/06] | AL | 26.05.2021 | |
AT | 26.05.2021 | ||
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
MC | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SI | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2022/29] | AL | 26.05.2021 | |
AT | 26.05.2021 | ||
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SI | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2022/26] | AL | 26.05.2021 | |
AT | 26.05.2021 | ||
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2022/23] | AT | 26.05.2021 | |
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2022/10] | AT | 26.05.2021 | |
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
EE | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
PT | 27.09.2021 | ||
IS | 22.12.2021 | ||
Former [2022/09] | AT | 26.05.2021 | |
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RO | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SK | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2022/08] | AT | 26.05.2021 | |
CZ | 26.05.2021 | ||
DK | 26.05.2021 | ||
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2022/07] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
SM | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2022/04] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
NL | 26.05.2021 | ||
PL | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2021/52] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
PL | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2021/51] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
RS | 26.05.2021 | ||
SE | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
IS | 26.09.2021 | ||
PT | 27.09.2021 | ||
Former [2021/50] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
SE | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
PT | 27.09.2021 | ||
Former [2021/49] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
HR | 26.05.2021 | ||
LT | 26.05.2021 | ||
LV | 26.05.2021 | ||
SE | 26.05.2021 | ||
BG | 26.08.2021 | ||
NO | 26.08.2021 | ||
GR | 27.08.2021 | ||
Former [2021/47] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
LT | 26.05.2021 | ||
BG | 26.08.2021 | ||
Former [2021/46] | AT | 26.05.2021 | |
FI | 26.05.2021 | ||
LT | 26.05.2021 | Cited in | International search | [YD]WO2010075074 (LILLY CO ELI [US], et al) [YD] 1-6 * page 3, lines 19-24 * * page 7, lines 5-8 * * page 52, line 24 - page 54, line 4 * * claims 13, 19 *; | [Y]WO2012097039 (LILLY CO ELI [US], et al) [Y] 7,8 * page 30, lines 17-24 * * page 31, lines 7-12 * * page 36, lines 11-19 * * page 37, lines 3-12 * * claims 1, 6, 10 *; | [YD]WO2013016081 (LILLY CO ELI [US], et al) [YD] 1-8 * page 33, line 26 - page 34, line 13 * * pages 40-41; table 2 * * page 41, lines 3-6 * * claims 1, 5 *; | [Y] - Mark H Bender, "Novel inhibitor of Notch signaling for the treatment of cancer", Cancer Res April 15, 2013 73, (20130415), page 1131, URL: http://cancerres.aacrjournals.org/content/73/8_Supplement/1131, (20160603), XP055277786 [Y] 1-8 * the whole document * | [Y] - Anonymous, "NCT02079636 on 2016_02_03: A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)", ClinicalTrials.gov Archive, (20160203), URL: https://clinicaltrials.gov/archive/NCT02079636/2016_02_03, (20170626), XP055384957 [Y] 1-8 * abstract * * page 2, paragraph l * * page 4, paragraph 2 * | [XP] - Anonymous, "NCT02784795 on 2016_05_26: A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", ClinicalTrials.gov Archive, (20160526), URL: https://clinicaltrials.gov/archive/NCT02784795/2016_05_26, (20170626), XP055384918 [XP] 1,3,5,7 * the whole document * | [YP] - Anonymous, "Notch Inhibitor Shows Modest Efficacy", Cancer Discovery, (20161214), pages 1 - 3, URL: http://cancerdiscovery.aacrjournals.org/content/early/2016/12/13/2159-8290.CD-NB2016-159, (20170629), XP055386303 [YP] 1,3,5,7 * the whole document * | Examination | - Cyriac Kandoth ET AL, "Mutational landscape and significance across 12 major cancer types", Nature, London, (20131001), vol. 502, no. 7471, doi:10.1038/nature12634, ISSN 0028-0836, pages 333 - 339, XP055614322 DOI: http://dx.doi.org/10.1038/nature12634 | by applicant | WO2010075074 | WO2013016081 | - JOSHI ET AL., BLOOD, (2009), vol. 113, no. 8, pages 1689 - 1698 | - RAO ET AL., CANCER RES., (2009), vol. 69, no. 7, pages 3060 - 3068 | - HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS | - S.M. BERGE ET AL., "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, (197701), vol. 66, no. 1, doi:doi:10.1002/jps.2600660104, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104 | - HOLFORD; SCHEINER, CLIN. PHARMACOKINET., (1981), vol. 6, pages 429 - 453 | - LOEWE; MUISCHENK, ARCH. EXP. PATHOL. PHARMACOL., (1926), vol. 114, pages 313 - 326 | - CHOU; TALALAY, ADV. ENZYME REGUL., (1984), vol. 22, pages 27 - 55 | - EISENHAUER ET AL., EUROPEAN JOURNAL OF CANCER, (2009), vol. 45, pages 228 - 247 | - EISENHAUER ET AL., EUR. J. CANCER, (2009), vol. 45, no. 2, pages 228 - 247 | - CHOI ET AL., J. CLIN. ONCOL., (2007), vol. 25, no. 13, pages 1753 - 1759 | - WEN ET AL., J. CLIN. ONCOL., (2010), vol. 28, no. 11, pages 1963 - 1972 | - OKEN ET AL., AM. J. CLIN. ONCOL., (1982), vol. 5, pages 649 - 655 |